您现在的位置: 首页   -  产品中心   -  免疫学   -   抗体
Human CCL3 Protein, hFc tag

Human CCL3 Protein, hFc tag

货号: S0A4063
价格: 1400
规格: 25μg
介绍: -
其他: -
产品规格
  • 物种

    Human
  • 分子别名

    C-C motif chemokine 3, G0/G1 switch regulatory protein 19-1, Macrophage inflammatory protein 1-alpha (MIP-1-alpha), PAT 464.1, SIS-beta, Small-inducible cytokine A3, Tonsillar lymphocyte LD78 alpha protein, G0S19-1, MIP1A, SCYA3
  • Accession

    P10147
  • 表达序列

    Protein sequence (P10147, Ser24-Ala92, with C-hFc tag) SLAADTPTACCFSYTSRQIPQNFIADYFETSSQCSKPGVIFLTKRSRQVCADPSEEWVQKYVSDLELSA

  • 表达宿主

    HEK293
  • 分子量

    Predicted MW: 33.8 kDa Observed MW: 40 kDa
  • 纯度

    >95% by SDS-PAGE
  • 内毒素含量

    <0.1EU/μg
  • 标记

    Unconjugated
  • 标签

    with C-hFc tag
  • 性状

    Lyophilized Powder
  • 缓冲体系

    Lyophilized from a 0.2 μm filtered solution of 0.2M PBS, pH7.4.
  • 溶解方法

    Reconstitute no more than 1 mg/mL according to the size in deionized water after rapid centrifugation.
  • 储存条件

    12 months from date of receipt, -20 to -70 °C as supplied.
    6 months, -20 to -70 °C under sterile conditions after reconstitution.
    1 week, 2 to 8 °C under sterile conditions after reconstitution.
    Please avoid repeated freeze-thaw cycles.

  • 稀释度

背景介绍
  • CCL3 is a cytokine belonging to the CC chemokine family that is involved in the acute inflammatory state in the recruitment and activation of polymorphonuclear leukocytes through binding to the receptors CCR1, CCR4 and CCR5. CCL3 produces a monophasic fever of rapid onset whose magnitude is equal to or greater than that of fevers produced with either recombinant human tumor necrosis factor or recombinant human interleukin-1. The fever induced by MIP-1 is not inhibited by the cyclooxygenase inhibitor ibuprofen and CCL3 may participate in the febrile response that is not mediated through prostaglandin synthesis and clinically cannot be ablated by cyclooxygenase. CCL3 has been shown to interact with CCL4. Attracts macrophages, monocytes and neutrophils.

  • 电泳JSON

    • 2μg(R: reducing conditions)